Actively Recruiting
A Real-World Observational Study of Diffuse Large B-Cell Lymphoma Patients With Different Genetic Subtypes
Led by Ruijin Hospital · Updated on 2024-12-19
10000
Participants Needed
1
Research Sites
169 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To collect and evaluate the data of real-world treatment regimen, efficacy, safety and survival information of DLBCL patients with different genetic suptypes
CONDITIONS
Official Title
Real-World Study of DLBCL With Different Genetic Subtypes
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically-confirmed diffuse large B-cell lymphoma (DLBCL)
- Genetic subtype belonging to at least one of the seven subtypes by using next generation sequencing: MCD, BN2, N1, ST2, A53, EZB (MYC+, MYC-) and others
- Fully comprehension and signature of the informed consent form (ICF) for participation
You will not qualify if you...
- Those who refuse to use reliable methods of contraception during pregnancy, lactation or age-appropriate period
- Severe mental illness
- Patients deemed unsuitable for inclusion by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China, 200025
Actively Recruiting
Research Team
W
Weili Zhao
P
Pengpeng Xu
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here